12月2日 - ** 药物开发商Sangamo Therapeutics SGMO.O股价上涨6%至0.47美元
** 该公司称美国食品和药物管理局（FDA）授予其治疗严重慢性神经痛的实验性疗法ST-503快速通道资格
** 该公司表示，ST-503 是一种实验性表观遗传调节剂，旨在提供非阿片类药物治疗选择
** 美国食品和药物管理局的 "快速通道 "标签旨在加快开发和审查用于治疗未满足医疗需求的严重疾病的药物
** 该公司预计将在未来几个月内为其早期试验的首例患者注射药物 - SGMO
** 包括本交易日的走势在内，该股今年累计下跌约 56
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.